GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Ceftolozane / tazobactam (Zerbaxa)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Record caution: Label-version change: the May 2026 DailyMed pediatric renal table is now local. Older pediatric evidence-gap statements remain historical; read the new age-specific source before selecting a regimen.

U.S. labeling, UCSF and Nebraska distinguish indication and infusion duration. Nebraska uses a 4-hour inpatient infusion; the label uses 1 hour. Keep each renal table with its indication and infusion method.

Check source scope before reading a dose

ZERBAXA - May 2026 pediatric renal regimens

Product / population
Pediatric ZERBAXA age 2 to below 18 with renal impairment; May 2026 label, Table 4. Doses are total ceftolozane+tazobactam.
Renal method
Validated pediatric eGFR, mL/min/1.73 m2; not adult Cockcroft-Gault.
Source revision
May 2026
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

One-hour labeling versus institutional extended infusion

The RX label table uses a one-hour infusion. The UCSF protocol uses a three-hour infusion. Both also separate urinary/intra-abdominal infection from pneumonia/severe infection.

What to reconcile: Keep the selected source dose, indication, renal band, loading instruction and infusion duration together.

Source difference identified; final patient-specific adjudication required.

Open this note and its source references

Pediatric renal guidance changed after the RX mirror

The older mirror lacks the age-specific renal regimens now supplied by the May 2026 label.

What to reconcile: Use the new pediatric card for ages two and older; verify indication, pediatric eGFR, weight caps and infusion time. Do not use adult Cockcroft-Gault bands as pediatric instructions.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Official

ZERBAXA - May 2026 pediatric renal regimens

Open original reference

DailyMed / Merck Sharp & Dohme LLC · Pediatric ZERBAXA age 2 to below 18 with renal impairment; May 2026 label, Table 4. Doses are total ceftolozane+tazobactam.

Renal method: Validated pediatric eGFR, mL/min/1.73 m2; not adult Cockcroft-Gault.
Source date: May 2026
Retrieved: 2026-09-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Age 2 to below 18 years: use a validated pediatric eGFR equation (mL/min/1.73 m2). For cIAI/cUTI, total combination mg/kg every eight hours at eGFR 51 to below 90, 30-50 and 15-29 are respectively 30, 15 and 7.5; infuse over one hour. For HABP/VABP, corresponding doses are 75, 37.5 and 18.75 mg/kg every eight hours over two hours. Intermittent HD: cIAI/cUTI loads 15 mg/kg then 3 mg/kg every eight hours; pneumonia loads 45 mg/kg then 9 mg/kg every eight hours. Give post-HD doses as early as possible after dialysis. Above 50 kg for cIAI/cUTI or 40 kg for pneumonia, do not exceed the adult renal dose. Below eGFR 15 without HD, dosing is not established. Renal-impairment dosing is not recommended below age two. Reassess changing eGFR daily. cIAI also requires metronidazole. These 2026 regimens supersede the older mirror's broad pediatric renal evidence gap.

RDM37-official-ceftolozane-tazobactam-3c655e39ee-C1 · Source locator: Sections 2.4 and 8.6, Table 4, including weight caps and dialysis footnotes.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70ac1d90-eff3-4f0b-9f46-5846c571b32f
Retrieved
2026-09-07
Exact label title
ZERBAXA - May 2026 pediatric renal regimens
DailyMed Set ID
70ac1d90-eff3-4f0b-9f46-5846c571b32f
Labeler
Merck Sharp & Dohme LLC
Label revision
May 2026
Renal-function method
Validated pediatric eGFR, mL/min/1.73 m2; not adult Cockcroft-Gault.
Source date/version
May 2026
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
fe69cdec610a3608ade3ea4c85fa30769fa7de9fef865a7a571642016e3a2ed1

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=ceftolozane-tazobactam&s1=RDM37-official-ceftolozane-tazobactam-3c655e39ee&h1=c44a149b8162380c3e687f68431f1508d501f37ac72f086a7c48eb877941df80